Skip to main content

Human Immunodeficiency Virus Infection

3
Pipeline Programs
7
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
375%
Peptide
125%
+ 4 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
extended-release exenatidePhase 4Peptide1 trial
Active Trials
NCT01791465Terminated6Est. Dec 2014
MSD
MSDIreland - Ballydine
1 program
1
lopinavir/ritonavirPhase 3Small Molecule1 trial
Active Trials
NCT00711009Completed206Est. Oct 2010
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
lopinavir/ritonavirPhase 3Small Molecule
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
Lopinavir / ritonavirN/ASmall Molecule
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)N/A
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Men Making a Difference HIV/STD Risk Reduction InterventionN/A1 trial
Active Trials
NCT01490359Completed1,181Est. Apr 2011
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
Men Making a Difference HIV/STD Risk Reduction InterventionN/A
Abbott
AbbottABBOTT PARK, IL
1 program
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)N/A1 trial
Active Trials
NCT01383005Completed97Est. Dec 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy Therapeuticsextended-release exenatide
MSDlopinavir/ritonavir
AbbottTreatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Human BioSciencesMen Making a Difference HIV/STD Risk Reduction Intervention

Clinical Trials (4)

Total enrollment: 1,490 patients across 4 trials

NCT01791465Allergy Therapeuticsextended-release exenatide

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

Start: Mar 2013Est. completion: Dec 20146 patients
Phase 4Terminated
NCT00711009MSDlopinavir/ritonavir

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Start: Jul 2008Est. completion: Oct 2010206 patients
Phase 3Completed
NCT01383005AbbottTreatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)

Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)

Start: Jun 2011Est. completion: Dec 201197 patients
N/ACompleted
NCT01490359Human BioSciencesMen Making a Difference HIV/STD Risk Reduction Intervention

Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men

Start: Nov 2007Est. completion: Apr 20111,181 patients
N/ACompleted

Related Jobs

【ViiV】Medical Manager

GSKGSK
Japan - Tokyo - Akasaka
3w ago

ViiV Healthcare (GSK) Head, Regional Medical Directors

GSKGSK
Field Worker - USA
3w ago

ViiV (GSK) US Competitive Intelligence & Market Research Lead

GSKGSK
USA - North Carolina - Durham
3w ago
$77K - $148K/yr

Marketing Director (m/f/d)

GSKGSK
Munich - Office
3w ago

Vaccine Sales - 南區 ,台南

GSKGSK
Field Worker - TWN
3w ago

Territory Account Manager - Minneapolis, MN

GSKGSK
USA - Minneapolis - Minneapolis
3w ago
$99K - $237K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.